ArticleJournal of industrial microbiology & biotechnology2017
5-Aminolevulinic acid production from inexpensive glucose by engineering the C4 pathway in Escherichia coli.
Article in Journal of industrial microbiology & biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 61 citations in OpenAlex.
- Systems metabolic engineering of dual pathways with stage-specific activation for high-level 5-aminolevulinic acid production inSynthetic and systems biotechnology · 2026Article
- Construction of a genome-engineered stable 5-aminolevulinic acid producingSynthetic and systems biotechnology · 2025Article
- On the Possibility of Using 5-Aminolevulinic Acid in the Light-Induced Destruction of Microorganisms.International journal of molecular sciences · 2024Review
- Applications of the Whole-Cell System in the Efficient Biosynthesis of Heme.International journal of molecular sciences · 2023Review
- Natural 5-Aminolevulinic Acid: Sources, Biosynthesis, Detection and Applications.Frontiers in bioengineering and biotechnology · 2022Review
- Modular control of multiple pathways of Corynebacterium glutamicum for 5-aminolevulinic acid production.AMB Express · 2021Article
- Challenges and opportunities of bioprocessing 5-aminolevulinic acid using genetic and metabolic engineering: a critical review.Bioresources and bioprocessing · 2021Review
- Plasmid-Free System and Modular Design for Efficient 5-Aminolevulinic Acid Production by Engineered Escherichia coli.Applied biochemistry and biotechnology · 2021Article
- Downregulating of hemB via synthetic antisense RNAs for improving 5-aminolevulinic acid production in3 Biotech · 2021Article
- Expanding application of CRISPR-Cas9 system in microorganisms.Synthetic and systems biotechnology · 2020Article
- CRISPR-Cas9/CRISPRi tools for cell factory construction in E. coli.World journal of microbiology & biotechnology · 2020Review
- Efficient bioproduction of 5-aminolevulinic acid, a promising biostimulant and nutrient, from renewable bioresources by engineeredBiotechnology for biofuels · 2020Article
- The Dark Side: Photosensitizer Prodrugs.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Different performance of3 Biotech · 2019Article
- Recent advances in production of 5-aminolevulinic acid using biological strategies.World journal of microbiology & biotechnology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
5-Aminolevulinic acid (ALA), the first committed intermediate for natural biosynthesis of tetrapyrrole compounds, has recently drawn intensive attention due to its broad potential applications. In this study, we describe the construction of recombinant Escherichia coli strains for ALA production from glucose via the C4 pathway. The hemA gene from Rhodobacter capsulatus was optimally overexpressed using a ribosome binding site engineering strategy, which enhanced ALA production substantially from 20 to 689 mg/L. Following optimization of biosynthesis pathways towards coenzyme A and precursor (glycine and succinyl-CoA), and downregulation of hemB expression, the production of ALA was further increased to 2.81 g/L in batch-fermentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.